-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the continuous transfer of global innovative drug outsourcing services to emerging Asian markets such as China, and the continuous complexity and refinement of the industrial chain of new drug R&D and production, the cost and the difficulty of R&D have increased.
The prosperity of the pharmaceutical outsourcing industry has continued to improve, and a large number of CXO companies have ushered in more benefits
.
Among them, especially the leading enterprises, the performance has shown a substantial growth trend
.
For example, the 2021 annual report released by WuXi PharmaTech recently showed that during the reporting period, the company achieved a revenue of 22.
902 billion yuan, a year-on-year increase of 38.
50%, and a net profit of 5.
097 billion yuan, a year-on-year increase of 72.
19%
.
From the perspective of subdivided businesses, the chemical business achieved revenue of 14.
087 billion yuan, a year-on-year increase of 46.
93%; the testing business achieved revenue of 4.
525 billion yuan, a year-on-year increase of 38.
03%; the biology business achieved revenue of 1.
985 billion yuan, a year-on-year increase of 30.
05%; domestic new drug research and development The service department realized revenue of 1.
251 billion yuan, a year-on-year increase of 17.
47%
.
For the substantial increase in performance, WuXi AppTec said that it is mainly due to the fact that in 2021, WuXi AppTec has provided services to more than 5,700 active customers in more than 30 countries around the world through 31 operating bases and branches around the world
.
On March 22, WuXi Biologics released its 2021 annual report, which also showed that its performance hit a new high
.
Specifically, in 2021, the company will realize a profit of 10.
290 billion yuan, a year-on-year increase of 83.
3%; the net profit and the net profit attributable to the owners of the company will reach 3.
509 billion yuan and 3.
389 billion yuan, respectively, a year-on-year increase of 107.
3% and 100.
6%
.
For the performance growth, WuXi Biologics said that there are three major factors that drive it.
First, the production business revenue has achieved significant growth; second, the new non-COVID-19 comprehensive projects have led to an increase in revenue and market share; third, the implementation of existing and new new crown projects has brought about Orders; fourth, implement the strategy of "follow and win molecules", add more late-stage clinical projects, and improve recent income; fifth, increase capacity utilization and operational efficiency
.
On February 24, Zhaoyan New Drug also disclosed the 2021 annual performance report.
The company will achieve operating income of 1.
517 billion yuan in 2021, a year-on-year increase of 40.
99%, and a net profit attributable to the parent of 557 million yuan, a year-on-year increase of 76.
83%
.
On the whole, the performance of Zhaoyan New Drug has maintained rapid growth, and the growth rate of profit is higher than that of revenue
.
In this regard, Zhaoyan New Drug said that it mainly comes from the following aspects: First, the company has always strengthened technological innovation, and first established and standardized the industry's innovative drug evaluation technology platform
.
Won the trust of innovative R&D enterprises, the new orders for the year exceeded 2.
8 billion yuan, and by the end of the reporting period, the orders in hand exceeded 2.
9 billion yuan
.
Secondly, the scale of the company's scientific research and technical team has expanded, with more and more mature technical personnel; further optimization and improvement of experimental facilities and project management processes have continued to improve laboratory capacity utilization to ensure efficient execution of orders in hand; Performance growth provided strong support
.
Third, the company continued to improve its capital management capabilities, which had a positive impact on the company's performance
.
The analysis believes that in the long run, innovation is still the main driving force for the development of the pharmaceutical industry
.
With the aging of the population and the acceleration of pharmaceutical innovation, innovative drug R&D companies still need to rely on pharmaceutical water sellers to break the bottleneck of high investment, long cycle and high risk, and continue to reduce R&D costs while improving R&D efficiency
.
In this context, there will continue to be a large demand in the pharmaceutical outsourcing industry in the future.
.
The industry predicts that the proportion of pharmaceutical R&D investment outsourcing will increase from 39.
4% in 2021 to 49.
9% in 2026, and the global pharmaceutical R&D investment outsourcing ratio will increase from 43.
0% in 2021 to 52.
7% in 2026
.
By 2025, the market for new drug R&D outsourcing services may reach $244 billion
.
In this context, domestic CXOs will be promising, and their performance may usher in new growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The prosperity of the pharmaceutical outsourcing industry has continued to improve, and a large number of CXO companies have ushered in more benefits
.
Among them, especially the leading enterprises, the performance has shown a substantial growth trend
.
For example, the 2021 annual report released by WuXi PharmaTech recently showed that during the reporting period, the company achieved a revenue of 22.
902 billion yuan, a year-on-year increase of 38.
50%, and a net profit of 5.
097 billion yuan, a year-on-year increase of 72.
19%
.
From the perspective of subdivided businesses, the chemical business achieved revenue of 14.
087 billion yuan, a year-on-year increase of 46.
93%; the testing business achieved revenue of 4.
525 billion yuan, a year-on-year increase of 38.
03%; the biology business achieved revenue of 1.
985 billion yuan, a year-on-year increase of 30.
05%; domestic new drug research and development The service department realized revenue of 1.
251 billion yuan, a year-on-year increase of 17.
47%
.
For the substantial increase in performance, WuXi AppTec said that it is mainly due to the fact that in 2021, WuXi AppTec has provided services to more than 5,700 active customers in more than 30 countries around the world through 31 operating bases and branches around the world
.
On March 22, WuXi Biologics released its 2021 annual report, which also showed that its performance hit a new high
.
Specifically, in 2021, the company will realize a profit of 10.
290 billion yuan, a year-on-year increase of 83.
3%; the net profit and the net profit attributable to the owners of the company will reach 3.
509 billion yuan and 3.
389 billion yuan, respectively, a year-on-year increase of 107.
3% and 100.
6%
.
For the performance growth, WuXi Biologics said that there are three major factors that drive it.
First, the production business revenue has achieved significant growth; second, the new non-COVID-19 comprehensive projects have led to an increase in revenue and market share; third, the implementation of existing and new new crown projects has brought about Orders; fourth, implement the strategy of "follow and win molecules", add more late-stage clinical projects, and improve recent income; fifth, increase capacity utilization and operational efficiency
.
On February 24, Zhaoyan New Drug also disclosed the 2021 annual performance report.
The company will achieve operating income of 1.
517 billion yuan in 2021, a year-on-year increase of 40.
99%, and a net profit attributable to the parent of 557 million yuan, a year-on-year increase of 76.
83%
.
On the whole, the performance of Zhaoyan New Drug has maintained rapid growth, and the growth rate of profit is higher than that of revenue
.
In this regard, Zhaoyan New Drug said that it mainly comes from the following aspects: First, the company has always strengthened technological innovation, and first established and standardized the industry's innovative drug evaluation technology platform
.
Won the trust of innovative R&D enterprises, the new orders for the year exceeded 2.
8 billion yuan, and by the end of the reporting period, the orders in hand exceeded 2.
9 billion yuan
.
Secondly, the scale of the company's scientific research and technical team has expanded, with more and more mature technical personnel; further optimization and improvement of experimental facilities and project management processes have continued to improve laboratory capacity utilization to ensure efficient execution of orders in hand; Performance growth provided strong support
.
Third, the company continued to improve its capital management capabilities, which had a positive impact on the company's performance
.
The analysis believes that in the long run, innovation is still the main driving force for the development of the pharmaceutical industry
.
With the aging of the population and the acceleration of pharmaceutical innovation, innovative drug R&D companies still need to rely on pharmaceutical water sellers to break the bottleneck of high investment, long cycle and high risk, and continue to reduce R&D costs while improving R&D efficiency
.
In this context, there will continue to be a large demand in the pharmaceutical outsourcing industry in the future.
.
The industry predicts that the proportion of pharmaceutical R&D investment outsourcing will increase from 39.
4% in 2021 to 49.
9% in 2026, and the global pharmaceutical R&D investment outsourcing ratio will increase from 43.
0% in 2021 to 52.
7% in 2026
.
By 2025, the market for new drug R&D outsourcing services may reach $244 billion
.
In this context, domestic CXOs will be promising, and their performance may usher in new growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
